Listen to the interview with Guidry News

A treatment pulled off the market 30 years ago has won FDA approval again as the only drug specifically designated to treat morning sickness in the United States. That long-ago safety scare, prompted by hundreds of lawsuits claiming birth defects, proved to be a false alarm. Last month’s FDA decision means a new version of the pill once called Bendectin is set to return to U.S. pharmacies under a different name — Diclegis. UTMB led the clinical trials of Diclegis that led to its approval. The news appeared in numerous outlets, including ABC News, the New York Times, WebMD, USA Today, Medical News Today, the New York Daily News, the Huffington Post, Medscape, KTRK Houston Channel 13, the Dallas Morning News and the Columbus Dispatch among many others.